Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Maze Therapeutics, Inc. (Nasdaq: MAZE) SEC filings page brings together the company’s public regulatory disclosures, offering a detailed view of how this clinical-stage biopharmaceutical company reports its activities to U.S. regulators. Maze focuses on small molecule precision medicines for kidney and metabolic diseases, and its filings provide context on both its scientific programs and its capital markets activity.
Maze’s filings include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, and financing transactions. For example, Maze has filed 8-Ks to furnish press releases on second and third quarter financial results, to disclose an oversubscribed private placement of common stock and pre-funded warrants, and to document the appointments of a new chief financial officer and a new chairman of the board.
Investors can also review registration statements, such as the company’s Form S-1, which describes Maze’s business, risk factors, and the resale of shares issued in its 2025 private placement. The S-1 outlines Maze’s focus on human genetics, its Compass platform, and its lead programs MZE829 and MZE782, while also confirming its status as an emerging growth company and smaller reporting company.
Through Stock Titan, these filings are updated in near real time from the SEC’s EDGAR system, and AI-powered summaries help explain the key points of lengthy documents. Users can quickly understand what a particular 8-K, S-1, or other filing means for the company without reading every page. Where applicable, filings related to equity financings, registration rights, and governance changes are highlighted so investors can track dilution, board composition, and executive appointments.
For MAZE, monitoring SEC filings is especially relevant for understanding clinical development disclosures, financing capacity, and risk factors associated with its kidney and metabolic disease programs. This page serves as a central resource for reviewing those official documents alongside concise AI-generated explanations.
Maze Therapeutics, Inc. (MAZE) discloses that officer Courtney Phillips has filed a notice of proposed sale of 4,144 shares of Common Stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney, with an indicated value of about $110,000 as of September 2, 2026 on Nasdaq.
The securities arise from restricted stock units that vested on September 1, 2026 as compensation from the issuer. The filing states the reported sale was mandated by the issuer and includes shares to satisfy tax withholding obligations related to that RSU vesting and settlement.
Maze Therapeutics, Inc. (MAZE) has a notice of proposed sale of common stock filed on behalf of officer Atul Dandekar under Rule 144. The stock relates to restricted stock units that vested as compensation, and the company mandated a sale of shares to cover tax withholding obligations tied to that vesting.
The notice also lists recent sales by Dandekar over the prior three months, each for 7,500 shares of Maze common stock, with aggregate proceeds a little above $200,000 per transaction.
Maze Therapeutics, Inc. (MAZE) received a notice under Rule 144 that officer Jason V. Coloma, through Morgan Stanley Smith Barney LLC, may sell up to 23,497 shares of common stock, with an indicated aggregate market value of $623,400, after September 2, 2026. The shares arise from restricted stock units that vested and settled on September 1, 2026, and the reported sale is mandated by Maze Therapeutics and includes shares needed to satisfy related tax withholding obligations. The notice also lists multiple recent sales of Maze common stock during the prior three months by the Coloma Family Trust and The Coloma 2021 Irrevocable Trust.
Maze Therapeutics, Inc. (MAZE) has a notice of proposed sale of common stock under Rule 144 filed for officer Harold Bernstein. Bernstein plans to sell 10,685 shares of common stock through Morgan Stanley Smith Barney LLC, with the shares arising from restricted stock units that vested on September 1, 2026.
The shares relate to an equity incentive award, and the company states the reported sale was mandated by the issuer and includes an amount necessary to satisfy tax withholding obligations from the vesting and settlement of those restricted stock units. The notice also lists several prior sales of Maze Therapeutics common stock by Bernstein over the past three months.
Maze Therapeutics, Inc. (MAZE) had a notice of proposed sale of common stock filed under Rule 144 for the account of officer Jason V. Coloma. The notice covers 34,501 shares of MAZE common stock held at UBS Financial Services Inc., with an indicated market value of $908,066.32 and 55,549,168 shares of common stock outstanding as of September 1, 2026. Recent sales over the prior three months were made by the Coloma Family Trust and The Coloma 2021 Irrevocable Trust, with multiple transactions in June, July, and August 2026.
Maze Therapeutics, Inc. (MAZE) officer Atul Dandekar (CSBO) reported an option exercise and same-day sale. On 2026-08-28, he exercised 7,500 stock options for common stock at an exercise price of $10.42 per share, receiving 7,500 shares, then sold 7,500 common shares at a weighted average price of $27.5765 per share in transactions ranging from $27.31 to $28.01. The option, which became fully vested on March 17, 2025, now has 14,143 options reported as remaining and expires on 2031-04-11. All reported trades were effected under a Rule 10b5-1 trading plan adopted on September 29, 2025.
Maze Therapeutics director Sophie Kornowski received a grant of 36,000 stock options on August 13, 2026. The options have an exercise price of $27.665 per share and expire on August 12, 2036. They vest in 36 equal monthly installments beginning September 13, 2026, contingent on her continued service.
Maze Therapeutics director Paula A. Johnson received a grant of stock options for 36,000 shares of common stock. The options have an exercise price of $27.665 per share, expire on August 12, 2036, and vest in 36 equal monthly installments starting September 13, 2026, subject to continued service.
Maze Therapeutics, Inc. (MAZE) reported that Sophie Kornowski filed an initial statement of beneficial ownership as a director on a Form 3. The filing lists no equity transactions, no derivative positions, and no reported share holdings, serving only to establish her status as an insider.
Maze Therapeutics, Inc. (MAZE) reported an initial statement of beneficial ownership for Paula A. Johnson, who is identified as a director. The filing lists no reportable transactions and no derivative positions, and the summary data shows no recorded share purchases, sales, or exercises at this time.